A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours

Capecitabine is a highly active oral fluoropyrimidine that is an attractive alternative to 5-fluorouracil in colorectal cancer treatment. The current study, undertaken in 27 patients with gastrointestinal tumours, aimed to assess the toxicity and potential for significant pharmacokinetic interaction...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Delord, J P, Pierga, J Y, Dieras, V, Bertheault-Cvitkovic, F, Turpin, F L, Lokiec, F, Lochon, I, Chatelut, E, Canal, P, Guimbaud, R, Mery-Mignard, D, Cornen, X, Mouri, Z, Bugat, R
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2005
Sujets:
Clinical Study
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361914/
https://ncbi.nlm.nih.gov/pubmed/15756252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602354
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires